Cancer and Metastasis Reviews

, Volume 13, Issue 3–4, pp 269–277 | Cite as

Aspirin, NSAIDs, and digestive tract cancers

  • Michael J. Thun
Article

Key words

aspirin NSAIDs nonsteroidal inflammatory drugs cancer (esophagus, stomach, colon, rectum) prostaglandin adenomatous polyps rheumatoid arthritis diet meat fruit vegetables 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Marnett LJ: Aspirin and the role of prostaglandins in cancer. Cancer Res 52: 5575–5589, 1992Google Scholar
  2. 2.
    Bennett A. Del Tacca M, Stamford IF, Zebro T: Prostaglandins from tumors of human large bowel. Br J Cancer 35: 881–884, 1977Google Scholar
  3. 3.
    Narisawa T, Kusaka H, Yamazaki Y,et al.: Relationship between blood plasma prostaglandin E2 and liver and lung metastases in colorectal cancer. Dis Colon Rectum 33: 840–845, 1990Google Scholar
  4. 4.
    Maxwell WJ, Kelleher D, Keating JJ,et al.: Enhanced secretion of prostaglandin E2 by tissue-fixed macrophages in colonic carcinoma. Digestion 47: 160–166, 1990Google Scholar
  5. 5.
    Karim SM, Rao B: Prostaglandins and tumors. In: Karim SMM (ed.) Advances in Prostaglandin Research, Vol. 2. MTP Press, Boston, 1976, pp 303–325Google Scholar
  6. 6.
    Hubbard WC, Alley MC, McLemore TL, Boyd MR: Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate and ovarian tumors. Cancer Res 48: 4770–4775, 1988Google Scholar
  7. 7.
    Hubbard WC, Alley MC, McLemore TL, Boyd MR: Fatty acid cyclooxygenase metabolism of arachidonic acid in human tumor cells. In: Honn KV, Marnett LJ, Nigam S, Welden Jr T (eds) Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury. Kluwer Academic Publishers, Norwell, M.A., 1991, pp 27–32Google Scholar
  8. 8.
    Pollard M, Luckert PH: Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 64: 1323–1327, 1980Google Scholar
  9. 9.
    Kudo T, Narisawa T, Abo S: Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann 71: 260–264, 1980Google Scholar
  10. 10.
    Pollard M, Luckert PH: Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 214: 558–559, 1981Google Scholar
  11. 11.
    Pollard M, Luckert PH: Treatment of chemically-induced intestinal cancers with indomethacin. Proc Soc Exp Biol Med 167: 161–164, 1981Google Scholar
  12. 12.
    Narisawa T, Sato M, Tani M, Kudo T, Takahashi T, Goto A: Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res 41: 1954–1957, 1981Google Scholar
  13. 13.
    Pollard M, Luckert PH, Schmidt MA: The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat. Cancer Lett 21: 57–61, 1983Google Scholar
  14. 14.
    Pollard M, Luckert PH: Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J Natl Cancer Inst 70: 1103–1105, 1983Google Scholar
  15. 15.
    Narisawa T, Satoh M, Sano M, Takahashi T: Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis 4: 1225–1227, 1983Google Scholar
  16. 16.
    Pollard M, Luckert PH: Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea. Cancer Lett 25: 117–121, 1984Google Scholar
  17. 17.
    Narisawa T, Hermanek P, Habs M, Schmahl D: Reduction of carcinogenicity of N-Nitrosomethylurea by indomethacin and failure of resuming effect of Prostaglandin E2 (PGE2) against indomethacin. J Cancer Res Clin Oncol 108: 239–242, 1984Google Scholar
  18. 18.
    Metzger U, Meier J, Uhlschmid G, Weihe H: Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis Colon Rectum 27: 366–369, 1984Google Scholar
  19. 19.
    Pollard M: Antitumor effect of indomethacin in rats with autochthonous intestinal tumors. In: Levin B, Riddell RH (eds) Frontiers in Gastrointestinal Cancer. Elsevier, New York, 1984, pp 91–103Google Scholar
  20. 20.
    Nigro DN, Bull AW, Boyd ME: Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 77: 1309–1313, 1986Google Scholar
  21. 21.
    Reddy BS, Maruyama H, Kelloff G: Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res 47: 5340–5346, 1987Google Scholar
  22. 22.
    Moorghen M, Ince P, Finney K, Sunter JP, Appleton DR, Watson AJ: A protective effect of sulindac against chemically-induced primary colonic tumors in mice. J Pathol 156: 341–347, 1988Google Scholar
  23. 23.
    Pollard M, Luckert PH: Prevention and treatment of primary intestinal tumors in rats by piroxicam. Cancer Res 49: 6471–6473, 1989Google Scholar
  24. 24.
    Rubio CA, Wallin B, Ware J, Sveander M, Duvander A: Effect of indomethacin in autotransplanted colonic tumors. Dis Colon Rectum 32: 488–491, 1989Google Scholar
  25. 25.
    Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G: Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal anti-inflammatory drug with D,L,-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 50: 2562–2568, 1990Google Scholar
  26. 26.
    Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS: Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, -difluoromethylornithine, 16-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 51: 4528–4534, 1991Google Scholar
  27. 27.
    Skinner SA, Penney AG, O'Brian PE: Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg 126: 1094–1096, 1991Google Scholar
  28. 28.
    Craven PA, Derubertis FR: Effects of aspirin on 1,-dimethylhydrazine-induced colonic carcinogenesis. Carcinogenesis 13: 541–546, 1992Google Scholar
  29. 29.
    Reddy BS, Rao CV, Rivenson A, Kelloff G: Inhibitory effects of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14: 1493–1497, 1993Google Scholar
  30. 30.
    Weisburger JH, Reddy BS, Joftes DL: Colorectal cancer. UICC Technical Report 19. UICC, Geneva, 1975Google Scholar
  31. 31.
    Waddell WR, Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 24: 83–87, 1983Google Scholar
  32. 32.
    Gonzaga RAF, Lima FR, Carneiro S, Maciel J, Junior MA: Sulindac treatment for familial polyposis coli. Lancet, March 1985, 751 (letter)Google Scholar
  33. 33.
    Friend WG: Sulindac suppression of colorectal polyps in Gardner's syndrome. AFP 41: 891–894Google Scholar
  34. 34.
    Waddell WR, Ganser GF, Cerise EJ, Loughry RW: Sulindac for polyposis of the colon. Am J Surg 157: 175–179, 1989Google Scholar
  35. 35.
    Rigau J, Pigué JM, Rubio E, Planas R, Tarrech JM, Bordas JM: Effects of long-term sulindac therapy on colonic polyposis. Ann Int Med 115: 952–954, 1991Google Scholar
  36. 36.
    Labayle D, Fischer D, Vielh P,et al.: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635–639, 1991Google Scholar
  37. 37.
    Giardiello FM, Hamilton SR, Krush AJ,et al.: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Eng J Med 328: 1313–1316, 1993Google Scholar
  38. 38.
    Peltomaki P, Aaltonen LA, Sistonen P,et al.: Genetic mapping of a locus predisposing to human colorectal cancer. Science 260: 810–818, 1993Google Scholar
  39. 39.
    Kune G, Kune S, Watson L: Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48: 4399–4404, 1988Google Scholar
  40. 40.
    Paganini-Hill A, Chao A, Ross RK, Henderson BE: Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 229: 1247–1250, 1989Google Scholar
  41. 41.
    Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S: A Hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83: 355–358, 1991Google Scholar
  42. 42.
    Thun M, Namboodiri M, Heath C: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593–1596, 1991Google Scholar
  43. 43.
    Thun M, Namboodiri M, Calle EE, Flanders WD, Heath CW: Aspirin use and risk of fatal cancer. Cancer Res 53: 1322–1327, 1993Google Scholar
  44. 44.
    Thun MJ, Calle EE, Namboodiri MM,et al.: Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst 84: 1491–1500, 1992Google Scholar
  45. 45.
    Logan RFA, Little J, Hawtin PG, Hardcastle JD: Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 307: 285–289, 1993Google Scholar
  46. 46.
    Paganini-Hill AL: Aspirin and colorectal cancer: seems to reduce risk. BMJ 307: 278–279 (editorial), 1993Google Scholar
  47. 47.
    Peleg II, Maibach HT, Brown SH, Wilcox CM: Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 154: 394–399, 1994Google Scholar
  48. 48.
    Suh O, Mettlin C, Petrelli NJ: Aspirin use, cancer, and polyps of the large bowel. Cancer 72: 1171–1177, 1993Google Scholar
  49. 49.
    Isomaki HA, Hakulinen T, Joutsenlahti U: Excess risk of lymphomas, leukemia, and myeloma in patients with rheumatoid arthritis. J Chron Dis 31: 691–696, 1978Google Scholar
  50. 50.
    Gridley G, McLaughlin JK, Ekbom A,et al.: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85: 307–311, 1993Google Scholar
  51. 51.
    Heath CW: heumatoid arthritis, aspirin, and gastrointestinal cancer. J Natl Cancer Inst 85: 258–259 (editorial), 1993Google Scholar
  52. 52.
    Greenberg ER, Baron JA, Freeman DH, Mandel JS, Haile R: Reduced risk of large-bowel adenomas among aspirin users. J Natl Cancer Inst 85: 912–916, 1993Google Scholar
  53. 53.
    Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138–146, 1994Google Scholar
  54. 54.
    Baron JA, Adami HO: A broad anticancer effect of aspirin? Epidemiology 5: 133–134 (editorial), 1994Google Scholar
  55. 55.
    Gann PH, Manson JE, Glynn J, Buring J, Hennekins CH: Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85: 1220–1224, 1993Google Scholar
  56. 56.
    Lipton A, Scialla S, Harvey H,et al.: Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer. J Med 23: 419–429, 1982Google Scholar
  57. 57.
    Vane J: Towards a better aspirin. Nature 367: 215–216, 1994Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Michael J. Thun
    • 1
  1. 1.Department of Epidemiology and StatisticsAmerican Cancer SocietyAtlantaUSA

Personalised recommendations